PLX Protalix Biotherapeutics Inc. (De)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.

$1.13  +0.03 (2.73%)
As of 12/02/2022 15:11:38 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/09/1996
Outstanding shares:  49,753,409
Average volume:  124,755
Market cap:   $54,728,750
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -2.30
PB ratio:   226.00
PS ratio:   1.27
Return on equity:   325.85%
Net income %:   -56.58%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy